Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

Mekinist: metastatic Non-small cell lung cancer with BRAF V600E

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

1.3 BRAF V600E Mutation-Positive Metastatic NSCLC MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test [see Dosage and Administration (2.1)] .

Broader topic: Non-Small Cell Lung Cancer

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
Not part of this definition
Biomarkers, prior therapy and derivation
molecular
  1. gene
    BRAF
    alteration
    V600E
    status
    present
prior therapy
    derivation status
    source-attested
    derivation note
    Scoped from the FDA approved indication for Mekinist (product label). Only dimensions stated in that wording are part of this definition.
    source wording
    1.3 BRAF V600E Mutation-Positive Metastatic NSCLC MEKINIST is indicated, in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test [see Dosage and Administration (2.1)] .

    Study evidence for this setting

    1 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

    NCT04985604 · Registry condition search · Scope: unclear

    Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

    6 outcome links · 2 safety-group records · 0 quality-of-life measures

    →
    Source relationships and population-mapping limitations
    bindings
      mappings

        Download this complete draft source relationship record →

        Preserved source evidence · Not medical advice